DOASENSE - Home - Pioneering Point-of-Care Testing for DOACs

Go to content
Pioneering Novel Approaches to Testing for DOACs
    • 2020-02: Industry Expert Remi Corlin joins DOASENSE as International Markets Consultant [read more]

    • 2020-01: DOASENSE will present its suite of point-of-care DOAC tests at these upcoming conferences:
              • ANIM, Karlsruhe (Germany) -  30 Jan - 1 Feb  (booth # 27)
              • GTH, Bremen (Germany) -  18 - 21 Feb  (booth # 65)

    • 2019-12: "Thrombosis and Haemostasis" editorial emphasizes the innovation of DOASENSE's DOAC Dipstick point-of-care test [read editorial], and publication on multicenter study favorably reviewed by NATA [read NATA review]

    • 2019-11: New publication on postmarketing multicenter study confirms strong performance of DOAC Dipstick point-of-care test for direct oral anticoagulants [article]

    • 2019-10: DOAC Dipstick featured in "Game Changer" section of new update on laboratory assessment for direct oral anticoagulants [article]

    • 2019-10: DOASENSE has appointed Haemoview Diagnostics (HVD) as exclusive distributor of its DOAC point-of-care test suite for Australia and New Zealand [Contact HVD]
      Distributor HITADO/SYSMEX serves
      Germany, Austria, and Switzerland
      [Contact HITADO]

    • 2019-09: DOASENSE exhibits at these upcoming fall 2019 conferences:
              • FELS, Freiburg (Germany) -  8 NOV
              • DGN, Stuttgart (Germany) -  25 - 27 SEPT
              • HAI, Berlin (Germany) -  19 - 20 SEPT

    • 2019-07: DOASENSE Announces Commercial Launch of the First Complete Suite of Products for Rapid Point-of-Care DOAC Testing [Read more]

More News [HERE]
When every minute counts … fast DOAC testing matters.

DOASENSE’s mission objective is changing the landscape of testing for DOACs (new synthetic oral anticoagulants) with novel and quick point-of-care urine tests

The determination of DOACs has long been limited to blood sampling approaches, with all their potential limitations, and a rapid assessment of the anticoagulant effect of non-vitamin K antagonist oral anticoagulants (Direct Oral AntiCoagulants – DOACs) by point-of-care testing (POCT) so far has been an unmet clinical need.

DOASENSE offers products for specific testing for DOACs in urine

Tests which are easy to use and easy to interpret, reproducible, and patient friendly

Listen to what opinion leaders think about DOASENSE's solutions:
Typical clinical scenarios where testing for specific DOACs can be of value

    • Stroke (e.g. before thrombolytic therapy)
    • Trauma
    • Emergency procedures
    • Evaluating for venous thromboembolism
    • Spontaneous hemorrhage
    • General surgery or invasive procedures
    • Other situations where medication history may not available

In each of these situations the objective is establishing the absence of DOACs in the patient prior to procedure
NOTE: DOASENSE(TM) products may not be available or approved in your country.

Copyright (c) 2016-2020 DOASENSE GmbH. All rights reserved.
Back to content